Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$7.25 USD
+0.26 (3.72%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $7.24 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.25 USD
+0.26 (3.72%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $7.24 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Zacks News
Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.
Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.
Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Reata (RETA) beats estimates for earnings and sales. Stock down on negative regulatory update on lead pipeline candidate, bardoxolone.
National Vision (EYE) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
National Vision (EYE) is expected to report sequentially better results for the second quarter on gradual reopening of stores and return toward more normal operations.
Why Larimar (LRMR) Might Surprise This Earnings Season
by Zacks Equity Research
Larimar (LRMR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
by Zacks Equity Research
Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.
Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.
Larimar (LRMR) Upgraded to Buy: Here's Why
by Zacks Equity Research
Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).